Sentynl took over the therapy’s development and commercialisation from Fortress Biotech's subsidiary Cyprium Therapeutics.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

A ccording to preliminary estimates, Light Vehicle (LV) sales grew by 2.4% year-on-year (YoY) in December, to 1.51 million ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Data from the largest US Lyme disease registry suggests that 90% of PLD patients are excluded from clinical trials.

In recent years, the oil and gas industry has progressed from using digital technologies for select use cases to making their ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...

The results of the trial align with earlier studies conducted in Europe, where UroShield improved patient outcomes.

About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

The heart failure market is expected to grow at a 9.6% CAGR from $13.5bn in 2022 to $33.7bn in 2032 in the 7MM.